Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 in Moderate-to-Severe Chronic Spontaneous Urticaria
NCT07764003Phase 2Not yet recruiting
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of girocitinib in chronic spontaneous urticaria (CSU), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
girocitinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07764003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764003.